- Q3 2022 Vivesto AB Earnings Call TranscriptNov 17, 2022$0.35Earnings
- Q2 2022 Vivesto AB Earnings Call TranscriptAug 25, 2022$0.1Earnings
- Q1 2022 Vivesto AB Earnings Call TranscriptMay 25, 2022$0.2253Earnings
- Q4 2021 Oasmia Pharmaceutical AB Earnings Call TranscriptFeb 24, 2022$0.525Earnings
- Oasmia Pharmaceutical AB Online Presentation TranscriptJan 19, 2022
- Q3 2021 Oasmia Pharmaceutical AB Earnings Call TranscriptNov 18, 2021$0.7135Earnings
- Q2 2021 Oasmia Pharmaceutical AB Earnings Call TranscriptAug 19, 2021$0.92255Earnings
- Oasmia Pharmaceutical AB (publ) - Special Call TranscriptMar 01, 2021
- Full Year 2020 Oasmia Pharmaceutical AB Earnings Call TranscriptFeb 19, 2021$1.1Earnings
- Q2 2021 Oasmia Pharmaceutical AB Earnings Call TranscriptDec 09, 2020$1.33Earnings
- LSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call TranscriptDec 03, 2020
- Vivesto AB at Sachs Associates Biotech in Europe Forum (Virtual) TranscriptSep 21, 2020
- Q1 2021 Oasmia Pharmaceutical AB Earnings Call TranscriptSep 09, 2020$1.67Earnings
- Q4 2020 Oasmia Pharmaceutical AB Earnings Call TranscriptJun 18, 2020$1.9Earnings
Q1 2022 Vivesto AB Earnings Call Transcript
Welcome to the Vivesto audio call with teleconference Q1 2022. (Operator Instructions)
May I present today, CEO, Francois Martelet. Please begin your meeting.
Thank you, and good morning, everyone. This morning, we released our Q1 2022 results, which we will be going through this presentation. And as usual, we'll run through the highlights and the financials and then take any questions at the end of this presentation.
So I'm now on Slide 1, which is a forward-looking statements that you should be aware. Slide 2, I have with me Fredrik Järrsten, our CFO. And let's move to Slide 3. So the first quarter of 2022 has seen us delivering sustained operational progress. And specific highlights include a successful rights issue, raising SEK 151 million to drive the development of our current business and programs. We also -- and I know that Fredrik will continue -- will go through that, we continue to reduce our operating expenses.
We have announced a manufacturing agreement with Lonza for clinical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)